Piramal Pharma Limited (PPLPHARMA) — Announcement | 18 August 2026

18 August 2026 · NSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Piramal Pharma completes acquisition of 40.67% stake in Yapan Bio.

🔄 What Changed

Ownership in Yapan increased from 33.33% to 74%; Yapan transitioned from associate to subsidiary.

💡 Investor Takeaway

The acquisition gives Piramal Pharma full control of Yapan's biologic manufacturing, strengthening its integrated service offering.

Piramal Pharma announced it completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its ownership from 33.33% to 74% and elevating Yapan from an associate to a subsidiary, thereby gaining full control over its advanced biologic manufacturing capabilities.

📄 View Original Announcement (PDF)

📊 Stock Analysis — PPLPHARMA ✨ Ask AI About This

About Piramal Pharma Limited (PPLPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹27,485.68 CrROE: -3.8%ROCE: 1.7%

View full PPLPHARMA stock details →

📡 Get AI alerts when PPLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track PPLPHARMA — Free

💡 Ask AI about this filing

"How will the ₹76 crore acquisition affect Piramal's earnings per share?""What is Yapan's revenue contribution to Piramal's total sales?""How does this stake change compare to Piramal's previous holdings in other associates?"

Ask AI Free →

📊 More PPLPHARMA filings

Announcement — 29 September 2026Piramal Pharma announced that its trading window will close on October 1, 2026, and remain shut for ...
🔴 Corporate Action — 29 September 2026Piramal Pharma disclosed a GST audit order requiring Rs. 4,06,03,220 in input tax credit demand and ...
🔴 Announcement — 18 September 2026Piramal Pharma disclosed that an independent ESG rating agency, Niche99, assigned it an ESG score of...
🔴 Announcement — 14 September 2026Piramal Pharma disclosed that the US FDA conducted a GMP inspection at its Morpeth, UK facility from...
🔴 Announcement — 8 September 2026Piramal Pharma announced its schedule for upcoming institutional investor meetings in late September...

See all PPLPHARMA filings →

🔥 Also filed on 18 August 2026

MURUDCERAMurudeshwar Ceramics LimitedAnnual Report LUXINDLux Industries LimitedCorporate Action MMPMMP Industries LimitedCorporate Action VADILALINDVadilal Industries LimitedCorporate Action ONESOURCEOnesource Specialty Pharma LimitedAnnouncement LUXINDLux Industries LimitedAnnual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when PPLPHARMA files new disclosures

Track PPLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.